![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
K V Pharma CL B | NYSE:KVB | NYSE | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
K-V Pharmaceutical Co. (KVA, KVB) has received permission from the U.S. Food and Drug Administration to return its first product to market following a successful inspection of facilities last month of the specialty-drug company.
Its Class A shares surged 59% premarket to $2.69. The stock had been down 54% this year.
The company has permission to manufacture and market two versions of its Micro-K, a potassium supplement. It is the latest in a number of regulatory and compliance issues the company has dealt with in recent years.
K-V stopped manufacturing and shipping all of its products in early 2009 and recalled most products already on the market, including Toprol, as it dealt with an FDA investigation into compliance matters and management misconduct, among others.
The company hadn't expected to be able to ship any product before the fourth quarter.
-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com
1 Year K V Pharma CL B Chart |
1 Month K V Pharma CL B Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions